Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure.

Haddad S, Wang Y, Galy B, Korf-Klingebiel M, Hirsch V, Baru AM, Rostami F, Reboll MR, Heineke J, Flögel U, Groos S, Renner A, Toischer K, Zimmermann F, Engeli S, Jordan J, Bauersachs J, Hentze MW, Wollert KC, Kempf T.

Eur Heart J. 2017 Feb 1;38(5):362-372. doi: 10.1093/eurheartj/ehw333.

PMID:
27545647
2.

The role of iron regulatory proteins in mammalian iron homeostasis and disease.

Rouault TA.

Nat Chem Biol. 2006 Aug;2(8):406-14. Review.

PMID:
16850017
3.

Heart failure in patients with kidney disease and iron deficiency; the role of iron therapy.

Cases Amenós A, Ojeda López R, Portolés Pérez JM; en representación del Grupo de Anemia de la S.E.N.

Nefrologia. 2017 Nov - Dec;37(6):587-591. doi: 10.1016/j.nefro.2017.03.027. Epub 2017 Jun 10. Review. English, Spanish.

4.

Iron regulatory proteins secure mitochondrial iron sufficiency and function.

Galy B, Ferring-Appel D, Sauer SW, Kaden S, Lyoumi S, Puy H, Kölker S, Gröne HJ, Hentze MW.

Cell Metab. 2010 Aug 4;12(2):194-201. doi: 10.1016/j.cmet.2010.06.007.

5.

Iron deficiency without anemia is responsible for decreased left ventricular function and reduced mitochondrial complex I activity in a mouse model.

Rineau E, Gaillard T, Gueguen N, Procaccio V, Henrion D, Prunier F, Lasocki S.

Int J Cardiol. 2018 Sep 1;266:206-212. doi: 10.1016/j.ijcard.2018.02.021.

PMID:
29887449
6.

Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.

Sabbah HN, Gupta RC, Kohli S, Wang M, Hachem S, Zhang K.

Circ Heart Fail. 2016 Feb;9(2):e002206. doi: 10.1161/CIRCHEARTFAILURE.115.002206.

7.

Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function.

Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, Rodenburg RJ, van Veldhuisen DJ, de Boer RA, van der Meer P.

Eur J Heart Fail. 2018 May;20(5):910-919. doi: 10.1002/ejhf.1154. Epub 2018 Feb 27.

8.

Excess capacity of the iron regulatory protein system.

Wang W, Di X, D'Agostino RB Jr, Torti SV, Torti FM.

J Biol Chem. 2007 Aug 24;282(34):24650-9. Epub 2007 Jun 28.

9.

Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.

Filippatos G, Farmakis D, Colet JC, Dickstein K, Lüscher TF, Willenheimer R, Parissis J, Gaudesius G, Mori C, von Eisenhart Rothe B, Greenlaw N, Ford I, Ponikowski P, Anker SD.

Eur J Heart Fail. 2013 Nov;15(11):1267-76. doi: 10.1093/eurjhf/hft099. Epub 2013 Jun 19.

10.

Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis.

Melenovsky V, Petrak J, Mracek T, Benes J, Borlaug BA, Nuskova H, Pluhacek T, Spatenka J, Kovalcikova J, Drahota Z, Kautzner J, Pirk J, Houstek J.

Eur J Heart Fail. 2017 Apr;19(4):522-530. doi: 10.1002/ejhf.640. Epub 2016 Sep 19.

11.
12.

The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.

Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Lüscher TF, Mori C, Willenheimer R, Ponikowski P, Anker SD.

Eur Heart J. 2013 Jan;34(1):30-8. doi: 10.1093/eurheartj/ehr504. Epub 2012 Jan 31.

13.

Iron regulatory protein-independent regulation of ferritin synthesis by nitrogen monoxide.

Mikhael M, Kim SF, Schranzhofer M, Soe-Lin S, Sheftel AD, Mullner EW, Ponka P.

FEBS J. 2006 Aug;273(16):3828-36. Erratum in: FEBS J. 2006 Oct;273(20):4805. Lin, Shan S [corrected to Soe-Lin, Shan].

14.

Recycling of RNA binding iron regulatory protein 1 into an aconitase after nitric oxide removal depends on mitochondrial ATP.

Bouton C, Chauveau MJ, Lazereg S, Drapier JC.

J Biol Chem. 2002 Aug 23;277(34):31220-7. Epub 2002 May 30.

15.

Iron regulatory proteins are essential for intestinal function and control key iron absorption molecules in the duodenum.

Galy B, Ferring-Appel D, Kaden S, Gröne HJ, Hentze MW.

Cell Metab. 2008 Jan;7(1):79-85. doi: 10.1016/j.cmet.2007.10.006.

16.

IRP1-independent alterations of cardiac iron metabolism in doxorubicin-treated mice.

Corna G, Galy B, Hentze MW, Cairo G.

J Mol Med (Berl). 2006 Jul;84(7):551-60. Epub 2006 Jun 13.

PMID:
16770644
17.

Beneficial effects of intravenous iron therapy in a rat model of heart failure with preserved systemic iron status but depleted intracellular cardiac stores.

Paterek A, Kępska M, Sochanowicz B, Chajduk E, Kołodziejczyk J, Polkowska-Motrenko H, Kruszewski M, Leszek P, Mackiewicz U, Mączewski M.

Sci Rep. 2018 Oct 25;8(1):15758. doi: 10.1038/s41598-018-33277-2.

18.

Ferric carboxymaltose in patients with heart failure and iron deficiency.

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators.

N Engl J Med. 2009 Dec 17;361(25):2436-48. doi: 10.1056/NEJMoa0908355. Epub 2009 Nov 17.

19.

Iron regulatory protein-1 and -2: transcriptome-wide definition of binding mRNAs and shaping of the cellular proteome by iron regulatory proteins.

Sanchez M, Galy B, Schwanhaeusser B, Blake J, Bähr-Ivacevic T, Benes V, Selbach M, Muckenthaler MU, Hentze MW.

Blood. 2011 Nov 24;118(22):e168-79. doi: 10.1182/blood-2011-04-343541. Epub 2011 Sep 22.

20.

Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis.

Anker SD, Kirwan BA, van Veldhuisen DJ, Filippatos G, Comin-Colet J, Ruschitzka F, Lüscher TF, Arutyunov GP, Motro M, Mori C, Roubert B, Pocock SJ, Ponikowski P.

Eur J Heart Fail. 2018 Jan;20(1):125-133. doi: 10.1002/ejhf.823. Epub 2017 Apr 24. Review.

Supplemental Content

Support Center